HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT

Karabatić, Sandra; Bećirević, Ilda; Lovrić, Božica; Jovanović, Tihomir

Health Bulletin, Vol. 12 No. 1, 2026.

Original scientific paper

HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT

Sandra Karabatić ; University Hospital Centre Zagreb, Kišpatićeva 12, 10 000 Zagreb, Croatia & Catholic University of Croatia, Ilica 244, 10 000 Zagreb, Croatia & University of Applied Sciences Ivanić-Grad, Moslavačka 11, 10 310 Ivanić-Grad, Croatia *
Ilda Bećirević ; Rotim Polyclinic, Miramarska cesta 24, 10 000 Zagreb, Croatia
Božica Lovrić ; Požega County General Hospital, Osječka 107, 34 000 Požega, Croatia & Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Crkvena 21, 31 000 Osijek, Croatia & University of Applied Sciences Ivanić-Grad, Moslavačka 11, 10 310 Ivanić-Grad, Croatia
Tihomir Jovanović ; Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Crkvena 21, 31 000 Osijek, Croatia & Pakrac General County Hospital and Croatian Veterans Hospital, Bolnička 74, 34 550 Pakrac, Croatia & Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Josipa Huttlera 4, 31 000 Osijek, Croatia

* Corresponding author.

Full text: english pdf 1.403 Kb

page 8-19

downloads: 0

cite

APA 6th Edition

Karabatić, S., Bećirević, I., Lovrić, B. & Jovanović, T. (2026). HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT. Zdravstveni glasnik, 12 (1), 8-19. Retrieved from https://hrcak.srce.hr/347490

MLA 8th Edition

Karabatić, Sandra, et al. "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT." Zdravstveni glasnik, vol. 12, no. 1, 2026, pp. 8-19. https://hrcak.srce.hr/347490. Accessed 30 May 2026.

Chicago 17th Edition

Karabatić, Sandra, Ilda Bećirević, Božica Lovrić and Tihomir Jovanović. "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT." Zdravstveni glasnik 12, no. 1 (2026): 8-19. https://hrcak.srce.hr/347490

Harvard

Karabatić, S., et al. (2026). 'HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT', Zdravstveni glasnik, 12(1), pp. 8-19. Available at: https://hrcak.srce.hr/347490 (Accessed 30 May 2026)

Vancouver

Karabatić S, Bećirević I, Lovrić B, Jovanović T. HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT. Zdravstveni glasnik [Internet]. 2026 [cited 2026 May 30];12(1):8-19. Available from: https://hrcak.srce.hr/347490

IEEE

S. Karabatić, I. Bećirević, B. Lovrić and T. Jovanović, "HEALTH-RELATED QUALITY OF LIFE IN LUNG CANCER PATIENTS ACCORDING TO TYPE OF TREATMENT", Zdravstveni glasnik, vol.12, no. 1, pp. 8-19, 2026. [Online]. Available: https://hrcak.srce.hr/347490. [Accessed: 30 May 2026]

Abstract

Background: Lung cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide, while quality of life has become an essential outcome measure in contemporary oncological care.
Aim: To assess the impact of different systemic treatment modalities on the quality of life of patients with lung cancer.
Methods: This prospective study was conducted between January and June 2022 at the Department for Lung and Mediastinal Tumors, Clinic for Pulmonary Diseases Jordanovac, University Hospital Centre Zagreb, Croatia. A total of 162 patients undergoing chemotherapy, immunotherapy, targeted therapy, or combined therapy following surgery were included. Quality of life was assessed using the EORTC QLQ-C30 questionnaire at baseline and two months after treatment initiation. Statistical analyses included the Wilcoxon signed-rank test and Kruskal–Wallis test.
Results: Global health status significantly improved two months after treatment initiation (P = 0.03), while fatigue (P = 0.04) and dyspnea (P = 0.04) decreased compared with baseline values. Financial difficulties increased significantly during treatment (P = 0.009). Patients receiving chemotherapy reported significantly poorer emotional (P = 0.002) and social functioning (P = 0.02) than those receiving immunotherapy. Cognitive functioning was significantly higher in patients treated with immunotherapy compared with chemotherapy or combined therapy (P = 0.001). Overall functioning (P = 0.01) and symptom burden (P = 0.005) were most favorable among patients receiving immunotherapy.
Conclusion: Treatment modality significantly affects quality of life in patients with lung cancer, with immunotherapy demonstrating the most favorable functional and symptomatic outcomes.